This trial is testing two different ways to close surgical ports. One is 2-Octylcyanoacrylate and the other is n-butyl-2-cyanoacrylate.
- Contact Dermatitis
2 Primary · 6 Secondary · Reporting Duration: 6 weeks
2 Treatment Groups
1 of 2
1 of 2
186 Total Participants · 2 Treatment Groups
Primary Treatment: Swiftset · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Does Swiftset meet the criteria for safety and efficacy set by the FDA?
"There is some evidence from earlier phases that Swiftset is effective, as well as data from multiple rounds of testing that support its safety--our team rates it a 3." - Anonymous Online Contributor
Are we still able to enroll new participants for this clinical study?
"This medical trial is currently looking for patients to enroll. According to the information on clinicaltrials.gov, the trial was originally posted on June 29th, 2022 and was last updated on August 11th, 2022." - Anonymous Online Contributor